Studies Currently Enrolling
ACHIEVE-4
Location(s): Jacksonville
This study includes patients with Type 2 Diabetes with cardiovascular disease on oral medications for the treatment of diabetes. Patients cannot be taking insulin or GLP-1 medications (such as Bydureon, Mounjaro, Ozempic, Trulicity or Victoza).
Learn moreBaxDuo-ARCTIC
Location(s): Jacksonville
Adults with kidney disease and high blood pressure may qualify for this study comparing baxdrostat in combination with dapagliflozin (Farxiga) versus dapagliflozin (Farxiga) alone. The study is assessing the efficacy, safety and tolerability of baxdrostat on the progression of kidney disease. Participants must be on a stable dose of an ACEi (for example benazepril, enalapril, or lisinopril) or ARB (for example losartan or valsartan) for at least one month prior to screening. Patients taking medications such as spironolactone, finerenone, triamterene, or similar may be excluded.
Learn moreCOMBINE 4
Location(s): Fleming Island
A study for patients with Type 2 Diabetes currently taking oral medication for diabetes and have an A1c between 7 and 10%. Patients cannot be using GLP-1 type mediations or insulin.
Learn moreAVANTI
Location(s): Fleming Island, Jacksonville & St. Augustine
This study is examining the efficacy and safety of Armour Thyroid compared to Synthroid for the treatment hypothyroidism. Adults age 18 to 75 years who are taking synthetic T4 (Synthroid, Levoxyl, Levothroid, or levothyroxine) may qualify. Patients who have undergone total thyroidectomy as treatment for thyroid cancer may be eligible.
Learn moreNN9388-7700
Location(s): Fleming Island
Study to evaluate the effects and safety of CagriSema in patients with chronic kidney disease and Type 2 Diabetes who are living with overweight or obesity. Patient cannot take GLP-1 medications (such as Bydureon, Mounjaro, Ozempic, Trulicity or Victoza) within 60 days of screening.
Learn moreNN9541-5015
Location(s): Fleming Island
This study is evaluating the safety and efficacy of investigational medication NNC0519-0130 administered in patients with overweight or obesity. NNC0519-0130 is under development for the treatment of obesity and Type 2 Diabetes. It acts by targeting GLP-1 and GIP.
Learn moreONWARDS 10
Location(s): Fleming Island
For adults with Type 2 Diabetes who currently take daily insulin, this study is evaluating the efficacy and safety of insulin icodec when switching from daily insulin. Patients may be assigned to once weekly insulin icodec or daily insulin glargine. This study excludes patients taking additional insulin with meals.
Learn moreREDEFINE 3
Location(s): St. Augustine
This study will evaluate the investigational medication CagriSema in obese patients 55 years or older with a history of heart attack, stroke, or peripheral artery disease. Patients with diabetes will be included as long as they are not taking a GLP-1 type medication. Patients cannot be using weight loss medications or have a history of weight loss surgery.
Learn moreREDEFINE 4
Location(s): Fleming Island
Enrolling patients who are overweight or obese and otherwise healthy. Patients cannot be taking weight loss medications or have a history of bariatric surgery.
Learn moreREIMAGINE 2
Location(s): Jacksonville
This study is being conducted to measure reduction in A1c using semaglutide and cagrilintide in patients with Type 2 Diabetes currently taking metformin only. Patients cannot be using GLP-1 type medications or weight loss medications, or have a history of weight loss surgery.
Learn moreREIMAGINE 4
Location(s): Jacksonville
Conducted in patients with Type 2 Diabetes taking metformin only. This study will measure weight loss and reduction in A1c. Patients cannot be using GLP-1 type medications, weight loss medications, or have a history of bariatric surgery or use of a weight loss device.
Learn moreREVITALIZE 1
Location(s): Fleming Island in partnership with Mayo Clinic in Jacksonville
A device study to assess blood sugar control in patients treated with Duodenal Mucosal Resurfacing using the Revita® System. This study includes patients with Type 2 Diabetes taking insulin and other diabetic medications.
Learn moreTRANSCEND-T2D 1
Location(s): Fleming Island
To demonstrate the superiority of retatrutide versus placebo in patients with Type 2 Diabetes and kidney disease. Patients taking daily insulin with or without metformin and/or a SGLT2 inhibitor (such as Brenzavvy, Invokana, Farxiga, Jardiance or Steglatro) may qualify.
Learn moreTRANSCEND-T2D 3
Location(s): Fleming Island
A study for adults with Type 2 Diabetes who are not currently treated with medication, and are using diet and exercise to control blood sugar. This study will compare retatrutide with placebo to demonstrate that retatrutide is superior in blood sugar control.
Learn moreW8M-MC-CWMM
Location(s): Fleming Island
This is a master protocol for a clinical trial evaluating multiple interventions for chronic weight management in adults who are overweight or obese. Patients will be excluded if they are using weight loss medications (including GLP-1 like medications) or had a prior surgical treatment for obesity.
Learn moreZEUS
Location(s): Fleming Island, Jacksonville & St. Augustine
For patients with established cardiovascular disease, kidney disease and systemic inflammation. This includes patients who have had: heart attack, stroke, heart surgery (stent or bypass), lower leg revascularization, or amputation above the ankle.
Learn more